Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(03): 35-38
DOI: 10.1055/s-0041-1733174
Selected Summary

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Roopa Hariprasad
Department of Medical Oncology, Institute Rotary Cancer Hospital, AIIMS, New Delhi-110029, India
,
Lalit Kumar
Department of Medical Oncology, Institute Rotary Cancer Hospital, AIIMS, New Delhi-110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
  • 2 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6,
  • 3 Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-1612.
  • 4 Markman M, Bundy BN, Alberts DS, Fowler JM, Clark- Pearson DL, Carson LF et al: Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001-7.
  • 5 Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34-43.
  • 6 Walker JL, Armstrong D, Huang HQ, Fowler J, Webster K, Burger RA, et al: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006; 100(1):27-32.
  • 7 Dedrick RL, Myers CE, Bungay PM & De Vita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978, 62:1-11.
  • 8 Goel R, Cleary SM, Horton C, Kirmani S, Abrahamson I, Kelly C et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 1989;81:1552-1560.
  • 9 Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr et al: Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study. J Clin Oncol 1992;10:1485-1491.
  • 10 Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12(3Suppl 4):1-6.
  • 11 Los G, Mutsaers PH, Lenglet WJ, Baldew GS & Mc Vie JG: Platinum distribution in intraperitoneal tumours after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol.1990;25(6):389-94.
  • 12 Yen MS, Juang CM, Lai CR, Chao GC, Ng HT &Yuan CC: Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet. 2001;72(1):55-60.
  • 13 Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A et al: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000;76(2):157-62.
  • 14 Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N et al: A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 1999;56(4):291-6.
  • 15 Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335(26):1950-5.